The study was an extension of Moderna’s Phase I safety trial, first conducted in individuals aged 18-55. It tested two doses of Moderna’s vaccine - 25 micrograms and 100 micrograms - in 40 adults aged 56 to 70 and 71 and older. One developed a grade three fever, which is classified as 102.2 degrees Fahrenheit (39°C) or above, after receiving the lower vaccine dose. “This is similar to what a lot of older adults are going to experience with the high dose influenza vaccine,” Anderson said. Hulme said he was aware Moderna’s vaccine employed a new technology, and that there might be a risk in taking it, but said, “somebody had to do it.”

Source: Standard Digital September 30, 2020 07:16 UTC